Correction to: The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain
Following publication of the original article [1], the authors reported that one of the numbers within Fig. 6 contains a mistake.
Main Authors: | M. Chris Runken, Paolo Caraceni, Javier Fernandez, Alexander Zipprich, Rashad Carlton, Martin Bunke |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | Health Economics Review |
Online Access: | http://link.springer.com/article/10.1186/s13561-020-00265-0 |
Similar Items
-
The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain
by: M. Chris Runken, et al.
Published: (2019-07-01) -
Neutrophil count to albumin ratio as a prognostic indicator for HBV-associated decompensated cirrhosis
by: Han, Z., et al.
Published: (2021) -
Correction of renal dysfunction in patients with the decompensated course of cirrhosis
by: A. S. Tugushev, et al.
Published: (2014-06-01) -
COVID-19 in decompensated cirrhosis
by: O. V. Tashchyan, et al.
Published: (2021-01-01) -
Improving Survival in Decompensated Cirrhosis
by: Amar Nath Mukerji, et al.
Published: (2012-01-01)